Abstract
Summary
Nucleic Acid Drug Raw Materials utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
LPI (LP Information)' newest research report, the “Nucleic Acid Drug Raw Materials Industry Forecast” looks at past sales and reviews total world Nucleic Acid Drug Raw Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid Drug Raw Materials sales for 2023 through 2029. With Nucleic Acid Drug Raw Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid Drug Raw Materials industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acid Drug Raw Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleic Acid Drug Raw Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nucleic Acid Drug Raw Materials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid Drug Raw Materials and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid Drug Raw Materials.
The global Nucleic Acid Drug Raw Materials market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nucleic Acid Drug Raw Materials players cover Danaher Corporation, Merck, Eurofins Scientific, Thermo Fisher Scientific, Agilent Technologies, GE Healthcare, Kaneka Eurogentec, GeneDesign and LGC Biosearch Technologies, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid Drug Raw Materials market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Research
Pharmaceutical
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Danaher Corporation
Merck
Eurofins Scientific
Thermo Fisher Scientific
Agilent Technologies
GE Healthcare
Kaneka Eurogentec
GeneDesign
LGC Biosearch Technologies
Bio-synthesis
Guangzhou RiboBio
STA Pharmaceutical
Hongene Biotech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleic Acid Drug Raw Materials market?
What factors are driving Nucleic Acid Drug Raw Materials market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleic Acid Drug Raw Materials market opportunities vary by end market size?
How does Nucleic Acid Drug Raw Materials break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Nucleic Acid Drug Raw Materials Industry Forecast” looks at past sales and reviews total world Nucleic Acid Drug Raw Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acid Drug Raw Materials sales for 2023 through 2029. With Nucleic Acid Drug Raw Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid Drug Raw Materials industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acid Drug Raw Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleic Acid Drug Raw Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Nucleic Acid Drug Raw Materials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acid Drug Raw Materials and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid Drug Raw Materials.
The global Nucleic Acid Drug Raw Materials market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nucleic Acid Drug Raw Materials is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nucleic Acid Drug Raw Materials players cover Danaher Corporation, Merck, Eurofins Scientific, Thermo Fisher Scientific, Agilent Technologies, GE Healthcare, Kaneka Eurogentec, GeneDesign and LGC Biosearch Technologies, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acid Drug Raw Materials market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Research
Pharmaceutical
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Danaher Corporation
Merck
Eurofins Scientific
Thermo Fisher Scientific
Agilent Technologies
GE Healthcare
Kaneka Eurogentec
GeneDesign
LGC Biosearch Technologies
Bio-synthesis
Guangzhou RiboBio
STA Pharmaceutical
Hongene Biotech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Nucleic Acid Drug Raw Materials market?
What factors are driving Nucleic Acid Drug Raw Materials market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleic Acid Drug Raw Materials market opportunities vary by end market size?
How does Nucleic Acid Drug Raw Materials break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acid Drug Raw Materials Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Nucleic Acid Drug Raw Materials by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Nucleic Acid Drug Raw Materials by Country/Region, 2018, 2022 & 2029
2.2 Nucleic Acid Drug Raw Materials Segment by Type
2.2.1 ASO
2.2.2 siRNA
2.2.3 Other
2.3 Nucleic Acid Drug Raw Materials Sales by Type
2.3.1 Global Nucleic Acid Drug Raw Materials Sales Market Share by Type (2018-2023)
2.3.2 Global Nucleic Acid Drug Raw Materials Revenue and Market Share by Type (2018-2023)
2.3.3 Global Nucleic Acid Drug Raw Materials Sale Price by Type (2018-2023)
2.4 Nucleic Acid Drug Raw Materials Segment by Application
2.4.1 Research
2.4.2 Pharmaceutical
2.4.3 Other
2.5 Nucleic Acid Drug Raw Materials Sales by Application
2.5.1 Global Nucleic Acid Drug Raw Materials Sale Market Share by Application (2018-2023)
2.5.2 Global Nucleic Acid Drug Raw Materials Revenue and Market Share by Application (2018-2023)
2.5.3 Global Nucleic Acid Drug Raw Materials Sale Price by Application (2018-2023)
3 Global Nucleic Acid Drug Raw Materials by Company
3.1 Global Nucleic Acid Drug Raw Materials Breakdown Data by Company
3.1.1 Global Nucleic Acid Drug Raw Materials Annual Sales by Company (2018-2023)
3.1.2 Global Nucleic Acid Drug Raw Materials Sales Market Share by Company (2018-2023)
3.2 Global Nucleic Acid Drug Raw Materials Annual Revenue by Company (2018-2023)
3.2.1 Global Nucleic Acid Drug Raw Materials Revenue by Company (2018-2023)
3.2.2 Global Nucleic Acid Drug Raw Materials Revenue Market Share by Company (2018-2023)
3.3 Global Nucleic Acid Drug Raw Materials Sale Price by Company
3.4 Key Manufacturers Nucleic Acid Drug Raw Materials Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nucleic Acid Drug Raw Materials Product Location Distribution
3.4.2 Players Nucleic Acid Drug Raw Materials Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Nucleic Acid Drug Raw Materials by Geographic Region
4.1 World Historic Nucleic Acid Drug Raw Materials Market Size by Geographic Region (2018-2023)
4.1.1 Global Nucleic Acid Drug Raw Materials Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Nucleic Acid Drug Raw Materials Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Nucleic Acid Drug Raw Materials Market Size by Country/Region (2018-2023)
4.2.1 Global Nucleic Acid Drug Raw Materials Annual Sales by Country/Region (2018-2023)
4.2.2 Global Nucleic Acid Drug Raw Materials Annual Revenue by Country/Region (2018-2023)
4.3 Americas Nucleic Acid Drug Raw Materials Sales Growth
4.4 APAC Nucleic Acid Drug Raw Materials Sales Growth
4.5 Europe Nucleic Acid Drug Raw Materials Sales Growth
4.6 Middle East & Africa Nucleic Acid Drug Raw Materials Sales Growth
5 Americas
5.1 Americas Nucleic Acid Drug Raw Materials Sales by Country
5.1.1 Americas Nucleic Acid Drug Raw Materials Sales by Country (2018-2023)
5.1.2 Americas Nucleic Acid Drug Raw Materials Revenue by Country (2018-2023)
5.2 Americas Nucleic Acid Drug Raw Materials Sales by Type
5.3 Americas Nucleic Acid Drug Raw Materials Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acid Drug Raw Materials Sales by Region
6.1.1 APAC Nucleic Acid Drug Raw Materials Sales by Region (2018-2023)
6.1.2 APAC Nucleic Acid Drug Raw Materials Revenue by Region (2018-2023)
6.2 APAC Nucleic Acid Drug Raw Materials Sales by Type
6.3 APAC Nucleic Acid Drug Raw Materials Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nucleic Acid Drug Raw Materials by Country
7.1.1 Europe Nucleic Acid Drug Raw Materials Sales by Country (2018-2023)
7.1.2 Europe Nucleic Acid Drug Raw Materials Revenue by Country (2018-2023)
7.2 Europe Nucleic Acid Drug Raw Materials Sales by Type
7.3 Europe Nucleic Acid Drug Raw Materials Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acid Drug Raw Materials by Country
8.1.1 Middle East & Africa Nucleic Acid Drug Raw Materials Sales by Country (2018-2023)
8.1.2 Middle East & Africa Nucleic Acid Drug Raw Materials Revenue by Country (2018-2023)
8.2 Middle East & Africa Nucleic Acid Drug Raw Materials Sales by Type
8.3 Middle East & Africa Nucleic Acid Drug Raw Materials Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nucleic Acid Drug Raw Materials
10.3 Manufacturing Process Analysis of Nucleic Acid Drug Raw Materials
10.4 Industry Chain Structure of Nucleic Acid Drug Raw Materials
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nucleic Acid Drug Raw Materials Distributors
11.3 Nucleic Acid Drug Raw Materials Customer
12 World Forecast Review for Nucleic Acid Drug Raw Materials by Geographic Region
12.1 Global Nucleic Acid Drug Raw Materials Market Size Forecast by Region
12.1.1 Global Nucleic Acid Drug Raw Materials Forecast by Region (2024-2029)
12.1.2 Global Nucleic Acid Drug Raw Materials Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Nucleic Acid Drug Raw Materials Forecast by Type
12.7 Global Nucleic Acid Drug Raw Materials Forecast by Application
13 Key Players Analysis
13.1 Danaher Corporation
13.1.1 Danaher Corporation Company Information
13.1.2 Danaher Corporation Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.1.3 Danaher Corporation Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Danaher Corporation Main Business Overview
13.1.5 Danaher Corporation Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.2.3 Merck Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Eurofins Scientific
13.3.1 Eurofins Scientific Company Information
13.3.2 Eurofins Scientific Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.3.3 Eurofins Scientific Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eurofins Scientific Main Business Overview
13.3.5 Eurofins Scientific Latest Developments
13.4 Thermo Fisher Scientific
13.4.1 Thermo Fisher Scientific Company Information
13.4.2 Thermo Fisher Scientific Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.4.3 Thermo Fisher Scientific Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Thermo Fisher Scientific Main Business Overview
13.4.5 Thermo Fisher Scientific Latest Developments
13.5 Agilent Technologies
13.5.1 Agilent Technologies Company Information
13.5.2 Agilent Technologies Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.5.3 Agilent Technologies Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Agilent Technologies Main Business Overview
13.5.5 Agilent Technologies Latest Developments
13.6 GE Healthcare
13.6.1 GE Healthcare Company Information
13.6.2 GE Healthcare Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.6.3 GE Healthcare Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 GE Healthcare Main Business Overview
13.6.5 GE Healthcare Latest Developments
13.7 Kaneka Eurogentec
13.7.1 Kaneka Eurogentec Company Information
13.7.2 Kaneka Eurogentec Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.7.3 Kaneka Eurogentec Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Kaneka Eurogentec Main Business Overview
13.7.5 Kaneka Eurogentec Latest Developments
13.8 GeneDesign
13.8.1 GeneDesign Company Information
13.8.2 GeneDesign Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.8.3 GeneDesign Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 GeneDesign Main Business Overview
13.8.5 GeneDesign Latest Developments
13.9 LGC Biosearch Technologies
13.9.1 LGC Biosearch Technologies Company Information
13.9.2 LGC Biosearch Technologies Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.9.3 LGC Biosearch Technologies Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 LGC Biosearch Technologies Main Business Overview
13.9.5 LGC Biosearch Technologies Latest Developments
13.10 Bio-synthesis
13.10.1 Bio-synthesis Company Information
13.10.2 Bio-synthesis Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.10.3 Bio-synthesis Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bio-synthesis Main Business Overview
13.10.5 Bio-synthesis Latest Developments
13.11 Guangzhou RiboBio
13.11.1 Guangzhou RiboBio Company Information
13.11.2 Guangzhou RiboBio Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.11.3 Guangzhou RiboBio Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Guangzhou RiboBio Main Business Overview
13.11.5 Guangzhou RiboBio Latest Developments
13.12 STA Pharmaceutical
13.12.1 STA Pharmaceutical Company Information
13.12.2 STA Pharmaceutical Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.12.3 STA Pharmaceutical Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 STA Pharmaceutical Main Business Overview
13.12.5 STA Pharmaceutical Latest Developments
13.13 Hongene Biotech
13.13.1 Hongene Biotech Company Information
13.13.2 Hongene Biotech Nucleic Acid Drug Raw Materials Product Portfolios and Specifications
13.13.3 Hongene Biotech Nucleic Acid Drug Raw Materials Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Hongene Biotech Main Business Overview
13.13.5 Hongene Biotech Latest Developments
14 Research Findings and Conclusion